Results 211 to 220 of about 315,624 (316)

Cardiovascular Dysfunction in Polycystic Ovary Syndrome: Mitochondrial and Inflammatory Mechanisms

BioMed Research International, Volume 2026, Issue 1, 2026.
Background Polycystic ovary syndrome (PCOS) is a common endocrine disorder that significantly increases cardiovascular disease (CVD) risk in women. While insulin resistance and dyslipidemia are established contributors, growing evidence highlights mitochondrial dysfunction and chronic low‐grade inflammation as central drivers of cardiovascular ...
Olabimpe Caroline Badejogbin, Mary Olaoluwa Agunloye, Ojichukwuka Ebere Chijioke-Agu, Makinde Vincent Olubiyi, Success Oluwanifesimi Olugbuyiro, Olaniyi Azeez Soetan, Opeyemi Abel Bamgbose, Tobi Opeyemi Olaleye, Swaran J. S. Flora   +8 more
wiley   +1 more source

A Potential Ratio for Detecting Subclinical Atherosclerosis: Insight into Advanced NMR Lipid Profiles in Severe Obesity. [PDF]

J Cardiovasc Transl Res
Carmona-Maurici J, Eskubi-Turró I, Viñas A, Ricart-Jané D, López-Tejero MD, Amigó N, Bermúdez M, Baena-Fustegueras JA, Peinado-Onsurbe J, Pardina E.   +9 more
europepmc   +1 more source

Protein deglycosylation can drastically affect the cellular uptake [PDF]

, 2019
Ghazaryan, A., Landfester, K., Mailänder, V.   +2 more
core   +2 more sources

In Vivo Therapeutic Potential of Biologically Synthesized Nanoparticles From Pine Needle Leaf Extract in Streptozotocin‐Induced Diabetic Rats

BioMed Research International, Volume 2026, Issue 1, 2026.
Background Diabetes mellitus (DM) is one of the most widespread metabolic diseases characterized by increased blood glucose levels. According to the most recent research, the treatment of diabetes could be improved with the use of green‐synthesized nanoparticles due to their biocompatibility, efficient cellular uptake, and targeted therapy.
Nourhane A. Darwich, Noura S. Abouzeinab, Ahmed F. El-Sayed, Rana El Hajj, Mahmoud I. Khalil, Rossana C. Zepeda   +5 more
wiley   +1 more source

Investigating the causal roles of cholesterol and triglyceride subfractions across lipoproteins in irritable bowel syndrome: a Mendelian randomization study. [PDF]

Metabol Open
Peng F, Xu K, Ba Q, Bi H, Lu Y.
europepmc   +1 more source

Distribution and transfer of cyclosporine among the various human lipoprotein classes [PDF]

, 1983
Graf, A., Illner, Wolf-Dieter, Land, Walter, Mraz, W., Preis, D., Siebert, W., Zink, R., Zöttlein, H.   +7 more
core   +1 more source

Epiafzelechin, a Flavanol, Regulates Lipid Homeostasis Through Modulation of HMGCR, PCSK9, and PPAR‐α: Mechanistic Insights and Therapeutic Implications

Cardiovascular Therapeutics, Volume 2026, Issue 1, 2026.
Hyperlipidemia remains a leading modifiable risk factor for cardiovascular morbidity and mortality. Statins are considered the cornerstone of treatment; however, their adverse effects and limited efficacy in certain patient populations necessitate exploration of novel therapeutic avenues. Epiafzelechin (EZN), a flavanol with established antioxidant and
Saud O. Alshammari, Nazifa Shahzad, Muhammad Nasir Hayat Malik, Qamar A. Alshammari, Abdulkarim Alshammari, Bassam S. M. Al Kazman, Muhammad Atif, Gideon F. B. Solre, Vivek Pandey   +8 more
wiley   +1 more source

Dysapolipoproteinaemia Influences the Relationship Between Very Low-Density Lipoprotein Cholesterol and Intra-Pancreatic Fat Deposition in Humans. [PDF]

Nutrients
Liu Y, Skudder-Hill L, Ko J, Shamaitijiang X, Sequeira-Bisson IR, Petrov MS.   +5 more
europepmc   +1 more source

Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media.

Arteriosclerosis, Thrombosis and Vascular Biology, 1995
B. Nordestgaard, R. Wootton, B. Lewis
semanticscholar   +1 more source

Efficacy and Safety of Olezarsen in Patients With Hypertriglyceridemia: A Meta‐Analysis of Randomized Controlled Trials

Cardiovascular Therapeutics, Volume 2026, Issue 1, 2026.
Aims Novel drugs that target apoC‐III in lipoprotein metabolism to reduce plasma triglycerides are currently under development. Olezarsen, a drug similar to its predecessor, volanesorsen, is in Phase 3 trials. A meta‐analysis of RCTs was done to study its effect on hypertriglyceridemia. Material and Methods Screening was done on PubMed, Embase, Scopus,
Kainat Feroz, Amna Parvez, Noor Ul Huda Ramzan, Tehreem Asghar, Ameer Haider Cheema, Ayesha Parvaiz Malik, Tehreem Fatima, Javed Iqbal, Brijesh Sathian, Soumya Patnaik   +9 more
wiley   +1 more source